Business
Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD(TM) Nano-Optic Lens Technology
Proprietary, patented technology providing vision protection beyond UV and Blue LightVancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that its proprietary, patented SPECTRAGUARD™ nano-optic lens technology is FDA registered and has been classified by the U.S. Food and Drug Administration (FDA) as a Class I...
About this update from Rise Nano Optics Ltd.
[{"type":"text","content":"Proprietary, patented technology providing vision protection beyond UV and Blue Light","length":85,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia—(Newsfile Corp. - March 23, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that its proprietary, patented SPECTRAGUARD™ nano-optic lens technology is FDA registered and has been classified by the U.S. Food and Drug Administration (FDA) as a Class I exempt medical device.","length":453,"tagName":"p"},{"type":"text","content":"The FDA has accepted the Company's stated intended use claim for SPECTRAGUARD™, which is designed to provide eye protection from bright sunlight by filtering 100% of ultraviolet (UV) light and up to 90% of wavelengths between 400-600 nm, including blue light, while preserving natural visual clarity and color perception.","length":325,"tagName":"p"},{"type":"text","content":"The FDA registration allows the Company to import its products and fully launch its commercialization efforts in the United States following its recent appointment of Erik Ritchie as Chief Commercial Officer. The company is executing a multi-channel commercialization strategy with sales targets including eye care professionals, lens manufacturers, optical labs, eyewear brands, and DTC platforms. The U.S. represents a significant revenue opportunity as one of the largest segments within the global US$160 billion eyewear market [1]. In the United States alone, more than 90 percent of adults use some form of eyewear [2], highlighting the scale of the addressable market particularly for individuals affected by prolonged screen exposure, light sensitivity, and degenerative eye conditions.","length":794,"tagName":"p"},{"type":"text","content":""This regulatory milestone represents an important de-risking event as we accelerate our commercialization strategy," said Inas Said, Founder and CEO of Rise Health Nano Optics. "FDA registration and Class I classification validate the safety profile and intended use of our SPECTRAGUARD™ technology and allow us to continue executing our multi-pronged commercialization strategy across North America, which includes lens man...